Clinical and pharmacological group: & nbsp

Immunosuppressive drugs

Other antineoplastic agents

Included in the formulation
  • Imnovid®
    capsules inwards 
    Selden International Sarl     Switzerland
  • АТХ:

    L.04.A.X.06   Pomalidomide

    Pharmacodynamics:

    Has a direct anti-myeloma, immunomodulatory effect on stromal cells supporting the growth of myeloma tumor cells. Selectively inhibits proliferation, causing apoptosis of tumor cells.

    Stimulates cellular immunity of T-killers, inhibits the synthesis of inflammatory cytokines by monocytes.

    It blocks the migration and adhesion of endothelial cells, thereby inhibiting angiogenesis.

    Pharmacokinetics:

    After oral administration, up to 73% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 2-3 hours. The connection with plasma proteins is 12-44%.

    Metabolism in the liver with the formation of inactive metabolites.

    The half-life is 7.5 hours. Elimination by the kidneys in the form of metabolites.

    Indications:

    It is used in combination with dexamethasone for the treatment of recurrent and multiple myeloma.

    II.C81-C96.C90.0   Multiple myeloma

    Contraindications:

    Age to 18 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Dysfunction of the liver, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category X.Contraindicated in pregnancy and lactation. Has a teratogenic effect.

    Dosing and Administration:

    Inside, 4 mg once a day for 21 days, then 40 mg per day for 1, 8, 15 and 22 days for a 28-day course.

    The highest daily dose: 40 mg.

    The highest single dose: 40 mg.

    Side effects:

    Central and peripheral nervous system: dizziness, insomnia, anxiety, confusion, peripheral neuropathy, acute disturbance of cerebral circulation.

    Respiratory system: cough, shortness of breath, interstitial pneumonitis, thromboembolism of the pulmonary artery.

    Hemopoietic system: thrombocytopenia, anemia, lymphopenia, neutropenia, thrombotic purpura.

    The cardiovascular system: arterial hypertension, hypertensive crisis, tachycardia, atrial fibrillation, myocardial infarction, pericarditis, deep vein thrombosis.

    Digestive system: dyspepsia, toothache, diarrhea, constipation, rarely - perforation of the gastrointestinal tract.

    Musculoskeletal system: arthralgia, myalgia, ossalgia, muscle spasms.

    Dermatological reactions: hyperhidrosis, itching, rash.

    Sense organs: cataract, visual impairment, vertigo.

    urinary system: renal failure.

    Allergic reactions.

    Overdose:

    Chills, kidney failure, cardiac arrest.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Monitoring of liver and kidney function.

    During treatment and within 3 months after its end, it is recommended to use reliable methods of contraception.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up